Olema Pharmaceuticals has confirmed the mechanism of action for its complete estrogen receptor antagonist (CERAN) palazestrant, which effectively recruits the corepressor protein NCoR1 to achieve full antagonism of the estrogen receptor (ER). This mechanism underpins palazestrant’s robust anti-tumor activity, particularly in estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer models. In combination with OP-3136, a novel KAT6 inhibitor, palazestrant exhibits synergistic anti-tumor effects by suppressing cell-cycle and ER-driven oncogenic signaling, highlighting its potential in overcoming acquired resistance in metastatic disease.

The findings presented at the AACR Annual Meeting indicate that palazestrant not only blocks ER-driven transcription but also demonstrates superior efficacy in downregulating key genes associated with cell proliferation compared to selective estrogen receptor modulators (SERMs). In preclinical studies, the combination of OP-3136 and palazestrant effectively downregulated oncogenic signaling pathways, including those linked to MYC, E2F, and MTORC1, suggesting a multifaceted approach to tackling resistance mechanisms in ER+ breast cancer. This positions palazestrant as a promising candidate for deeper and more consistent ER pathway suppression.

The implications of these findings are significant for the field of breast cancer therapeutics. By demonstrating the potential of combining palazestrant with OP-3136, this research paves the way for new treatment paradigms that could enhance the efficacy of existing therapies and shorten drug development timelines for patients with ER+/HER2- metastatic breast cancer. As palazestrant moves through Phase 3 trials, the results may redefine standards of care and provide a more effective strategy for managing this challenging cancer subtype.

Source: globenewswire.com